LAS VEGAS, Feb. 22, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce it has filed a patent application to protect SP-04 as a new and novel compound to defend and protect the body against exposure to bioterrorism attacks of nerve gas agents.
Chemical weapons have been used in wars since the early 1900s. Of the thousands of highly poisonous chemicals, experts believe that terrorists will choose to use nerve agents because of their toxicity. In modern war, protecting soldiers against any kind of threat and preserving their ability to fight has become a major concern of armies, as they have to face new deadly threats on, and off, the battlefield.
Nerve agents attack the nervous system of the human body. Generally, nerve agents function by interrupting the breakdown of the neurotransmitters that signal muscles to contract, preventing them from relaxing.
Dr. Greeson, CEO of Samaritan Pharmaceuticals stated, "Unprotected contact with nerve gas leads to certain death if appropriate and effective treatment is not administered very quickly. Preclinical data has demonstrated SP-04's unique ability to act on various neural receptor systems, and at the same time, increase the antioxidant defense of the body against nerve gas. This data suggests SP-04 as a novel and improved antidote against nerve gas agents which necessitated the filing of a patent application to protect its claims."
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
Click here: Samaritan Pharmaceuticals -- Samaritan Technology Videos (http://www.samaritanpharma.com/html/videos.html)
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.